A novel quasi-viral agent, MaTu, is a two-component system
about
sameAs
Characterization of non-specific cytotoxic cell receptor protein 1: a new member of the lectin-type subfamily of F-box proteinsExpression of the hypoxia-inducible and tumor-associated carbonic anhydrases in ductal carcinoma in situ of the breastThe prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapyPrognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-AnalysisIs carbonic anhydrase IX a validated target for molecular imaging of cancer and hypoxia?Recent developments in targeting carbonic anhydrase IX for cancer therapeuticsNew insights into intra- and intermolecular interactions of immunoglobulins: crystal structure of mouse IgG2b-Fc at 2·1-Å resolutionCarbonic anhydrase isozymes IX and XII in gastric tumorsExpression of von Hippel-Lindau tumor suppressor and tumor-associated carbonic anhydrases IX and XII in normal and neoplastic colorectal mucosaHuman tumour-associated cell adhesion protein MN/CA IX: identification of M75 epitope and of the region mediating cell adhesion.Carbonic anhydrase IX in oligodendroglial brain tumors.Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancerUnique biological properties of catalytic domain directed human anti-CAIX antibodies discovered through phage-display technologyThe tumour-associated carbonic anhydrases CA II, CA IX and CA XII in a group of medulloblastomas and supratentorial primitive neuroectodermal tumours: an association of CA IX with poor prognosis.Prognostic value of intratumoral carbonic anhydrase IX expression in testicular germ cell tumors.Expression of vascular notch ligand delta-like 4 and inflammatory markers in breast cancerTumour necrosis is a postoperative prognostic marker for pancreatic cancer patients with a high interobserver reproducibility in histological evaluation.Optimization of a novel peptide ligand targeting human carbonic anhydrase IXRole of hypoxia and EGF on expression, activity, localization and phosphorylation of carbonic anhydrase IX in MDA-MB-231 breast cancer cells.Arginase II expressed in cancer-associated fibroblasts indicates tissue hypoxia and predicts poor outcome in patients with pancreatic cancerExpression of hypoxic marker CA IX is regulated by site-specific DNA methylation and is associated with the histology of gastric cancer.Biochemical characterization of CA IX, one of the most active carbonic anhydrase isozymes.Catalysis and pH control by membrane-associated carbonic anhydrase IX in MDA-MB-231 breast cancer cellsMeasuring carbonic anhydrase IX as a hypoxia biomarker: differences in concentrations in serum and plasma using a commercial enzyme-linked immunosorbent assay due to influences of metal ions.Carbonic anhydrase inhibitor suppresses invasion of renal cancer cells in vitro.Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer.Carbonic anhydrase IX is a predictive marker of doxorubicin resistance in early-stage breast cancer independent of HER2 and TOP2A amplification.Role of zinc in catalytic activity of carbonic anhydrase IX.Carbonic anhydrases in normal gastrointestinal tract and gastrointestinal tumours.Carbonic anhydrase IX is a clinically significant tissue and serum biomarker associated with renal cell carcinomaAlternative splicing variant of the hypoxia marker carbonic anhydrase IX expressed independently of hypoxia and tumour phenotypeHypoxia-regulated carbonic anhydrase IX expression is associated with poor survival in patients with invasive breast cancer.Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progressionSoluble form of carbonic anhydrase IX (CA IX) in the serum and urine of renal carcinoma patients.pVHL and PTEN tumour suppressor proteins cooperatively suppress kidney cyst formation.Combined VHLH and PTEN mutation causes genital tract cystadenoma and squamous metaplasia.Identification of an alternatively spliced isoform of carbonic anhydrase XII in diffusely infiltrating astrocytic gliomasPrognostic value of serum carbonic anhydrase IX in testicular germ cell tumor patients.Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours.
P2860
Q24297525-6E82A203-5642-46FC-844E-95483B442DBEQ24685857-82615190-1A4D-4D27-905E-63D79425D73EQ24801373-FAA66E13-3BA7-46DC-9376-40D3A9A83E9CQ26749393-C8095C2F-8C26-4513-8827-1549A391DD14Q26849504-9B3464AC-4B2A-4946-BF16-E1777EBFB7D8Q27013023-19330591-9913-4A74-9D6D-13EE0665A847Q27652073-4F4F9561-BD3D-42D6-AD04-96C5D98063A1Q28186386-5BC76018-284C-4359-811B-696047C88830Q28246673-4731C6A8-24F2-47DC-85EF-84941FBF640AQ30875554-411285ED-4D88-45CA-98A7-48FA5CA3AE22Q33313215-8317B76C-536F-4A9C-BA44-048AC8BE998EQ33484460-7B62BA7F-8B97-4436-8657-01EA8DDFE0A1Q33540178-1EE40DD6-DA66-41D1-BBD0-0CEABB9E9DDEQ33557891-F055E01D-0AC3-4275-9AB5-B6386887F09FQ33598505-286A17A8-C25A-4B35-A65F-F22B1A7FD960Q33745294-CF53CF5F-AA7B-443D-8388-939E70BA2919Q34250138-5D53EA54-ECC9-4043-8E64-85EDE30DC852Q34302457-3E7A9D9D-F9A9-4B7C-BCC5-AB9D88C12B40Q34459093-76C68399-7BC3-4505-9498-267873EACAD6Q34592559-E9630A86-A489-4F2B-BD09-B7CEEEA5DFB2Q34756174-A2967CC4-83B9-4AAE-AD9E-9C9D80A16BDDQ34808815-5D3C14C1-ADB2-43AB-B031-AA78C92F22D3Q34963089-0707CD5B-5C7E-4420-8FB5-1D9612B7388FQ35015917-6E760EB0-2A39-447A-B193-EA9B23FED6AEQ35051535-259B0913-E379-4E35-B3CC-A81FA60C67DCQ35451764-759D55CD-33D0-4541-942D-5076BDDE03E5Q35588327-0C3D689B-6DA4-49EA-A9BD-B92C921E1F71Q35835151-55C1AAB8-BDE1-49FE-8330-BAD7D20429D0Q35935908-1E2FE610-E464-454E-B7DB-E9535A839D06Q36000418-5A9AA53B-CFE8-4341-94CD-1AAE162D0186Q36475753-8C75B040-D6C4-4005-9C01-8BCA95E4E2ECQ36608750-EE82D7D2-6AFE-4FCF-AAEA-E08287542B78Q36610569-36DB3538-91C6-4418-A0A2-2D272A393A6BQ36615803-6716A39B-864B-485D-B201-2F23A8BACE7DQ36648463-5A97E6B1-E4BA-40C5-A539-509285A908ACQ36731316-DB4D78A3-BAC0-48E8-91FC-4634806F76BEQ36748085-1142AC9B-C665-4CBB-A692-43769D67B408Q37036905-BDBB2C55-1F37-42F3-9AD4-311966D4E8F2Q37288442-8683529E-901E-42B0-BBE3-32CE9B2D2F66Q37330712-7C0BA643-080B-4A45-842F-EE713002FBD0
P2860
A novel quasi-viral agent, MaTu, is a two-component system
description
1992 nî lūn-bûn
@nan
1992 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
A novel quasi-viral agent, MaTu, is a two-component system
@ast
A novel quasi-viral agent, MaTu, is a two-component system
@en
A novel quasi-viral agent, MaTu, is a two-component system
@nl
type
label
A novel quasi-viral agent, MaTu, is a two-component system
@ast
A novel quasi-viral agent, MaTu, is a two-component system
@en
A novel quasi-viral agent, MaTu, is a two-component system
@nl
prefLabel
A novel quasi-viral agent, MaTu, is a two-component system
@ast
A novel quasi-viral agent, MaTu, is a two-component system
@en
A novel quasi-viral agent, MaTu, is a two-component system
@nl
P2093
P3181
P1433
P1476
A novel quasi-viral agent, MaTu, is a two-component system
@en
P2093
O Babusíková
S Pastoreková
Z Závadová
P3181
P356
10.1016/0042-6822(92)90464-Z
P407
P577
1992-04-01T00:00:00Z